Skip to Content

Join the 'Aflibercept' group to help and get support from people like you.

Aflibercept News

Experimental Drug Shows Promise for Sight-Stealing Eye Condition

Posted 18 Jan 2017 by

WEDNESDAY, Jan. 18, 2017 – An experimental drug may one day make treatment simpler for patients suffering from vision-threatening age-related macular degeneration, researchers say. So far, the drug – called AXT107 – has been only tested on mice and rabbits, but it requires far fewer injections than current therapy to prevent vision loss. Current treatment requires frequent injections directly ...

Study Compares Drugs for Common Diabetic Eye Disease

Posted 29 Feb 2016 by

MONDAY, Feb. 29, 2016 – People with diabetes are at risk for blurred vision or even a loss of vision from a condition called macular edema. Three drugs for the disease – Avastin, Eylea and Lucentis – vary widely in price, but new research suggests all work equally well for patients with mild vision loss. However, when diabetic macular edema leads to more severe vision loss, researchers found ...

Eylea Approval Expanded to Include Diabetic Retinopathy

Posted 26 Mar 2015 by

WEDNESDAY, March 25, 2015 – U.S. Food and Drug Administration approval of Eylea (aflibercept) has been expanded to treat diabetic retinopathy among people with diabetic macular edema, the agency said Wednesday in a news release. Affecting more than 29 million people in the U.S., diabetic retinopathy is the most common diabetic eye disease and a leading cause of blindness, the FDA said. Among ...

FDA Approves Eylea (aflibercept) for Diabetic Retinopathy in Patients with Diabetic Macular Edema

Posted 25 Mar 2015 by

March 25, 2015 – The U.S. Food and Drug Administration today expanded the approved use for Eylea (aflibercept) injection to treat diabetic retinopathy in patients with diabetic macular edema. Diabetic retinopathy (DR) is the most common diabetic eye disease and is a leading cause of blindness in adults in the United States. According to the Centers for Disease Control and Prevention, diabetes ...

Eylea (aflibercept) Injection Receives FDA Approval for the Treatment of Diabetic Macular Edema

Posted 31 Jul 2014 by

TARRYTOWN, N.Y., July 29, 2014 /PRNewswire/ – Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Eylea (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). The recommended dosage of Eylea in patients with DME is 2 milligrams (mg) every two months (8 weeks) after five initial monthly injections. ...

Ask a Question

Further Information

Related Condition Support Groups

Macular Degeneration, Diabetic Macular Edema, Macular Edema, Diabetic Retinopathy

Related Drug Support Groups


Aflibercept Patient Information at